ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Plans CHF500 Million New Manufacturing Facility

ZURICH -(Dow Jones)- Swiss pharmaceutical company Novartis AG (NVS) said Monday it is planning to invest over 500 million Swiss francs ($550 million) building a new manufacturing facility in Switzerland. MAIN FACTS: -The company said the investment underlines the long-term strategy of Novartis to establish a worldwide manufacturing network of technology centers. -The new production site in Stein, Switzerland, is expected to be fully operational by end of 2016. -"This investment is further strengthening the importance of Stein as Manufacturing Center of Excellence for sterile and solid dosage forms and will play a key role in our global production network," said Joseph Jimenez, CEO of Novartis. "It also strengthens our presence in Switzerland, which remains a center of key importance for Novartis." -The Stein site in Canton Aargau is the largest production facility of the Pharmaceuticals Division. Every year, the approximately 1,400 associates at the site produce over 4.1 billion tablets, capsules, ampoules, prefilled syringes, vials and transdermal therapeutic systems, which are exported to over 150 countries. -The new set-up will allow Novartis to adapt its production capacity more quickly depending on an evolving portfolio and market demand. The center will serve approximately 150 markets globally. -Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/27/201617:10:00Amgen Profit Rises 13%, 2016 Outlook Raised
07/26/201608:00:00Eli Lilly Revenue Rise Helped by New Products
07/25/201616:10:00Stada Arzneimittel Feels More Heat From Active Ownership
07/21/201612:50:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/20/201603:05:00Business Watch -- WSJ
07/19/201619:00:00ADRs End Lower; Ericsson Falls
07/19/201604:36:00Novartis Warns on Profit as It Boosts Investment in Heart-Failure...
07/19/201603:40:00Novartis Warns on Profit as Entresto Investment Weighs
07/19/201602:25:00Novartis Warns Profit Could Fall This Year Due to Increased Spending...
07/15/201611:01:00Novartis AG 2Q 2016 - Forecast
07/12/201619:20:00Amgen Biosimilar Gets Thumbs-Up From FDA Panel
06/06/201605:11:00Mereo BioPharma to Trade on AIM -- Update
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/20/201615:20:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/20/201615:18:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/18/201603:03:00Novartis Says Drug-Unit Chief To Leave Firm -- WSJ
05/17/201618:43:00ADRs End Lower; NQ Mobile Rises
05/17/201615:11:00Novartis to Split Pharmaceuticals Division into Two -- Update
05/17/201614:10:00Novartis to Split Drug Division
05/17/201613:27:00Novartis to Split Pharmaceuticals Division Into Two

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad